心調律管理装置：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
3 Competitive Assessment 13
3.1 Overview 13
3.2 Global Market Share 13
3.2.1 Pacemaker and CRT-P Market Company Share Globally 13
3.2.2 ICD and CRT-D Market Company Share Globally 15
3.3 Regional Market Share 16
3.3.1 Pacemaker and CRT-P Market Company Share in the US 16
3.3.2 ICD and CRT-D Market Company Share in the US 17
3.3.3 Pacemaker and CRT-P Company Share in Europe 18
3.3.4 ICD and CRT-D Market Company Share in Europe 19
3.3.5 Pacemaker and CRT-P Market Company Share in Emerging Markets 20
3.3.6 ICD and CRT-D Market Company Share in Emerging Markets 21
3.3.7 Pacemaker and CRT-P Market Company Share in Japan 22
3.3.8 ICD and CRT-D Market Company Share in Japan 23
4 Pipeline Products 24
4.1 Overview 24
4.2 Pipeline Products by Phase in Development 24
4.3 Pacemaker and CRT-P Product Profiles 25
4.3.1 Aortic Pacemaker (Hadasit Medical Research Services & Development Ltd.) 25
4.3.2 Cardiac Energy Harvesting Pacemaker (University of Michigan) 26
4.3.3 Endurance Microgenerator (Endurance Rhythm) 26
4.3.4 Implantable Dual-Chamber Pacemaker (MicroPort Scientific) 27
4.3.5 Unconditional MRI-Compatible Implantable Pacemaker (Kenergy, Inc.) 27
4.3.6 Tissue-Engineered Autonomous Pacemaker (Duke University) 28
4.3.7 Wireless Cardiac Stimulation Device (EBR Systems, Inc.) 28
4.4 ICD and CRT-D Product Profiles 29
4.4.1 Atrial Defibrillator (SmartWave Medical Ltd.) 29
4.4.2 CardiaLen (CardiaLen, Inc.) 29
4.4.3 Chronicle (Medtronic) 30
4.5 Clinical Trials to Watch 31
4.5.1 Overview 31
4.5.2 SELECT-LV Trial of WiCS-LV System (EBR Systems, Inc.) 31
4.5.3 MultiPoint Pacing Clinical Trial of Quadra Assura CRT-D (Medtronic) 33
4.5.4 MADIT-ASIA Trial with Invive CRT-P (Boston Scientific) 34
4.5.5 MultiPoint Pacing IDE Study of Promote Quadra (St. Jude Medical) 36
4.5.6 Post Approval Study of S-ICD System (Boston Scientific) 37
4.5.7 ProMRI Study of the Evia/Entovis Pacemaker System 39
4.5.8 MIRACLE EF Clinical Study of Consulta CRT-P (Medtronic) 41
5 Current and Future Players 44
5.1 Overview 44
5.2 Trends in Corporate Strategy 44
5.3 Biotronik 45
5.3.1 Overview 45
5.3.2 Portfolio Evaluation 47
5.3.3 Commercial Positioning 57
5.3.4 Company SWOT Analysis 58
5.4 Boston Scientific 58
5.4.1 Overview 58
5.4.2 Portfolio Evaluation 60
5.4.3 Commercial Positioning 69
5.4.4 Company SWOT Analysis 70
5.5 Impulse Dynamics 70
5.5.1 Overview 70
5.5.2 Portfolio Evaluation 70
5.5.3 Commercial Positioning 71
5.5.4 Company SWOT Analysis 71
5.6 Medtronic 72
5.6.1 Overview 72
5.6.2 Portfolio Evaluation 74
5.6.3 Marketed Products 76
5.6.4 Additional Products 84
5.6.5 Commercial Positioning 86
5.6.6 Company SWOT Analysis 88
5.7 Sorin Group 88
5.7.1 Overview 88
5.7.2 Portfolio Evaluation 90
5.7.3 Marketed Products 91
5.7.4 Commercial Positioning 92
5.7.5 Company SWOT Analysis 93
5.8 St. Jude Medical 93
5.8.1 Overview 93
5.8.2 Portfolio Evaluation 94
5.8.3 Marketed Products 96
5.8.4 Commercial Positioning 109
5.8.5 Company SWOT Analysis 110
6 Appendix 111
6.1 Bibliography 111
6.2 Abbreviations 124
6.3 Report Methodology 129
6.3.1 Overview 129
6.3.2 Coverage 129
6.3.3 Secondary Research 129
6.3.4 Forecasting Methodology 130
6.3.5 Primary Research – Key Opinion Leader Interviews 131
6.3.6 Expert Panel Validation 132
6.4 Physicians and Specialists Included in this Study 132
6.5 About the Authors 134
6.5.1 Analysts 134
6.5.2 Global Head of Healthcare 135
6.6 About MediPoint 136
6.7 About GlobalData 136
6.8 Disclaimer 136